Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) was the recipient of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 3,211,049 shares, a growth of 275.7% from the June 15th total of 854,672 shares. Based on an average daily trading volume, of 4,938,871 shares, the short-interest ratio is currently 0.7 days. Approximately 3.7% of the company’s stock are short sold.
Institutional Investors Weigh In On Context Therapeutics
A number of institutional investors have recently modified their holdings of CNTX. Blue Owl Capital Holdings LP lifted its holdings in Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after acquiring an additional 25,000 shares during the last quarter. Octagon Capital Advisors LP acquired a new stake in shares of Context Therapeutics during the 1st quarter worth approximately $13,755,000. Vanguard Group Inc. raised its position in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the period. Millennium Management LLC bought a new stake in shares of Context Therapeutics in the 4th quarter worth approximately $3,824,000. Finally, Marshall Wace LLP boosted its position in Context Therapeutics by 7,153.7% during the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the period. Institutional investors own 14.03% of the company’s stock.
Context Therapeutics Stock Performance
Shares of NASDAQ CNTX traded up $0.01 during trading on Tuesday, reaching $0.63. The stock had a trading volume of 577,208 shares, compared to its average volume of 1,844,916. The stock has a market cap of $57.79 million, a PE ratio of -1.50 and a beta of 1.75. Context Therapeutics has a one year low of $0.55 and a one year high of $3.62. The firm’s 50 day moving average price is $1.57 and its two-hundred day moving average price is $2.03.
Wall Street Analyst Weigh In
CNTX has been the subject of a number of recent analyst reports. Guggenheim restated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Maxim Group decreased their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Piper Sandler increased their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, March 24th. Finally, Wall Street Zen raised shares of Context Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.
View Our Latest Stock Report on CNTX
About Context Therapeutics
Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.
With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.
Featured Articles
- Five stocks we like better than Context Therapeutics
- 3 Energy Stocks Racing to Fix AI’s Power Problem
- No Space For Panic: T-Mobile Shrugs Off The Starlink Threat
- Prepare for the Next Wave of Factory Automation With These 3 Standout Names
- These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
